Gavin MacBeath
2022
In 2022, Gavin MacBeath earned a total compensation of $1.4M as Acting Chief Executive Officer, Chief Scientific and Operating Officer at TScan Therapeutics, a 14% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $188,000 |
|---|---|
| Option Awards | $711,554 |
| Salary | $450,000 |
| Other | $12,173 |
| Total | $1,361,727 |
MacBeath received $711.6K in option awards, accounting for 52% of the total pay in 2022.
MacBeath also received $188K in non-equity incentive plan, $450K in salary and $12.2K in other compensation.
Rankings
In 2022, Gavin MacBeath's compensation ranked 2,434th out of 5,756 executives tracked by ExecPay. In other words, MacBeath earned more than 57.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,434 out of 5,756 | 58th |
Division Manufacturing | 1,333 out of 3,133 | 58th |
Major group Chemicals And Allied Products | 601 out of 1,419 | 58th |
Industry group Drugs | 555 out of 1,320 | 58th |
Industry Biological Products, Except Diagnostic Substances | 138 out of 291 | 53rd |
Source: SEC filing on April 25, 2023.
MacBeath's colleagues
We found two more compensation records of executives who worked with Gavin MacBeath at TScan Therapeutics in 2022.